Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Firms Sift Eye Study Data For Benefit From Lutein And Zeaxanthin

This article was originally published in The Tan Sheet

Executive Summary

After the Age-Related Eye Disease Study found lutein, zeaxanthin and omega-3s do not slow age-related macular degeneration, supplement firms revisit the data and find lutein and zeaxanthin could slow the disease in deficient populations.

You may also be interested in...



Wellness Market News: Abbott Nutrition Q3 Up 1.6%, Easier-To-Swallow PreserVision AREDS, More

Ensure, Glucerna brands boost Abbott Nutrition adult product third-quarter sales 3.9% on reported basis to $830m; Baush + Lomb relaunches PreserVision AREDS 2 Formula soft gels with easier-to-swallow option; Hum Nutrition Mighty Night supplement boosts skin cell renewal during sleep; and NOW Health Group acquires family-owned SuperNutrition.

Vision Health Supplements Blurry On AREDS Formulation – Study

A study finds claims for ocular supplements cited or relied on AREDS findings even when the products did not match the formulas assessed in the research by NIH’s National Eye Institute. The products emphasize AREDS but offer little information to consumers, they say.

Vision Health Supplements Blurry On AREDS Formulation – Study

A study finds claims for ocular supplements cited or relied on AREDS findings even when the products did not match the formulas assessed in the research by NIH’s National Eye Institute. The products emphasize AREDS but offer little information to consumers, they say.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel